How to Help Your Patients Save Money on Elahere: A Provider's Guide to Savings Programs

Elahere (mirvetuximab soravtansine-gynx) is a transformative therapy for patients with FRα-positive, platinum-resistant ovarian cancer — but at approximately $29,307 per treatment cycle, cost and coverage issues frequently delay or prevent treatment initiation. For oncology practices and their teams, proactive engagement with financial assistance resources is essential to ensuring patients can actually begin and sustain Elahere therapy. This provider guide covers every major savings pathway available in 2026.

Understanding How Elahere Is Billed: Medical Benefit vs. Pharmacy Benefit

Elahere is billed through the medical benefit (under Part B for Medicare patients), not the pharmacy benefit. This distinction matters significantly for patient cost-sharing:

Under the medical benefit, patients with commercial insurance typically pay a coinsurance percentage (e.g., 20%) after meeting their deductible — which can be very costly for a high-priced biologic.

Medicare Part B enrollees face a standard 20% coinsurance with no out-of-pocket cap (until the annual deductible/MOOP thresholds apply), meaning costs can run to tens of thousands per year without supplemental coverage.

Standard pharmacy discount programs (GoodRx, SingleCare, etc.) do not apply to medical-benefit drugs.

Program 1: ELAHERE Support Services (ESS) — Co-Pay Assistance

AbbVie's ELAHERE Support Services program is the primary resource for patient financial assistance. Your practice should enroll eligible patients proactively — ideally at the same time the Elahere prescription is written.

Co-pay Assistance Card: For commercially insured patients who meet eligibility criteria, the ESS co-pay card covers co-pays and coinsurance, potentially reducing out-of-pocket costs to $0 per cycle.

Eligibility: Must have commercial insurance that covers Elahere; not available for Medicare, Medicaid, TRICARE, or other government programs.

Enrollment: Submit the ESS enrollment form from your office, or call 1-833-ELAHERE (1-833-352-4373). ESS assigns a Case Manager to the patient within 1-2 business days.

Case Managers also assist with prior authorization submissions, appeals, and infusion center coordination.

Program 2: Patient Assistance Program (PAP) — Free Drug for Uninsured/Underinsured

For patients without sufficient coverage, AbbVie's Patient Assistance Program (myAbbVie Assist) provides free Elahere to qualifying patients:

Eligibility: U.S. residents (including Puerto Rico) who are uninsured or whose insurance does not cover Elahere, and who meet income-based financial eligibility criteria.

Medicare note: Patients with Medicare Part D under 150% Federal Poverty Level must show proof of Medicare Extra Help/LIS denial before qualifying.

Application: Submit through ESS (1-833-352-4373) or at myAbbVie Assist (1-800-222-6885).

Program 3: Independent Non-Profit Foundations — For Medicare/Medicaid Patients

Patients on Medicare, Medicaid, or TRICARE are ineligible for manufacturer co-pay assistance (per OIG anti-kickback guidelines) but may qualify for independent non-profit co-pay grants. As part of patient support, consider referring these patients to:

Patient Advocate Foundation (PAF) Co-Pay Relief: Provides co-pay grants for specific diseases including ovarian cancer. Check copays.patientadvocate.org for open funds.

HealthWell Foundation: Offers disease-specific grants; check if an ovarian cancer or oncology fund is open at healthwellfoundation.org.

CancerCare Co-Payment Assistance Foundation: Provides limited grants for cancer patients to cover treatment co-pays.

Ovarian Cancer Research Alliance (OCRA) Patient Navigation: OCRA provides a helpline (1-866-399-6262) to connect patients with financial resources.

These funds are limited and often have open/closed cycles. Encourage patients to apply as early as possible — ideally before the first infusion.

Program 4: Prior Authorization and Appeals Best Practices

Proactively building a strong PA submission reduces denial rates and shortens the time to first treatment. A winning PA package for Elahere should include:

Positive VENTANA FOLR1 assay result (include the lab report, not just a notation)

Platinum-resistance documentation (progression within 6 months of last platinum dose — include treatment dates and imaging reports)

Prior lines of therapy (1-3) — names, dates, outcomes

Reference to full FDA approval (March 22, 2024) and NCCN Guidelines Category 1 recommendation

Compelling letter of medical necessity citing the MIRASOL trial: OS HR 0.67 (p=0.0046), ORR 42.3% vs 15.9%, first therapy ever to improve OS in PROC

If a PA is denied, file a peer-to-peer review request immediately. An oncologist-to-medical-director conversation citing clinical trial evidence frequently overturns initial denials for FDA-approved, guideline-supported therapies.

Building a Financial Navigation Workflow in Your Practice

To minimize treatment delays, consider building a standard workflow for Elahere patients:

At FRα testing: Identify insurance type and flag potential PAP-eligible patients

At FRα-positive result: Immediately submit ESS enrollment form and begin PA preparation

For Medicare/Medicaid patients: Begin foundation grant applications concurrently with PA

If PA denied: Peer-to-peer review within 48-72 hours; involve ESS Case Manager for appeals

At treatment start: Confirm co-pay card or PAP enrollment is active before first infusion

For patients who need help locating infusion facilities, medfinder for providers helps identify nearby facilities that can administer Elahere, so your patients aren't delayed by logistical barriers after financial hurdles are cleared.

Related reading: Elahere Shortage: What Providers and Prescribers Need to Know in 2026.